INCY Incyte Corporation
Company Analysis
Latest News
🟢 Incyte Corporation is trading 4.1% up today as investors cheer the company's largest-ever acquisition
Incyte Corporation is trading 4.1% up at $107.43 as the stock continues to rally following a major strategic move. • On June 8, 2026, Incyte announced its...
Incyte Shareholders Approve All Proposals at 2026 Annual Meeting
Incyte Corporation announced the results of its Annual Meeting of Shareholders held on June 8, 2026, where stockholders approved all proposals, including the...
🔴 Incyte Corporation is trading 4.4% down today after announcing a $2 billion acquisition of Vega Therapeutics
Incyte Corporation is trading 4.4% down at $96.22 after announcing a major acquisition of Vega Therapeutics for up to $2.0 billion, including $1.25 billion...
Incyte to Acquire Vega Therapeutics for up to $2.0 Billion, Expanding Hematology Portfolio
Incyte Corporation announced a definitive agreement to acquire Vega Therapeutics, Inc., a subsidiary of Star Therapeutics, for an upfront payment of $1.25...
Incyte Nears $2 Billion Star Therapeutics Deal, Targeting Bleeding Disorder Drug
Incyte is reportedly nearing a $2 billion acquisition of privately held Star Therapeutics. The agreement includes a $1.25 billion upfront cash payment....
🟢 Incyte Corporation is trading 4.4% up today as it extends a three-day rebound
Incyte Corporation is trading 4.4% up at $105.72 on momentum and dip-buying as the stock extends a three-day recovery from levels below $93. • The move...
🟢 Incyte Corporation is trading 4.4% up today, extending a three-day rebound despite broader market weakness
Incyte Corporation is trading 4.4% up at $105.67, extending a sharp three-day rebound from below $93 despite broader U.S. indices trading lower. • The move...